Related Experiment Video
Updated: Apr 18, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
14.0K
[Thalidomide, cereblon and multiple myeloma].
Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 29, 2015
Summary
Immunomodulatory drugs (IMiDs) like lenalidomide target Cereblon (CRBN) to degrade transcription factors. This mechanism is key for treating multiple myeloma, showing promising therapeutic applications.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Cereblon (CRBN) identified as a direct target of thalidomide.
- This discovery spurred research into immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide.
- IMiDs modulate CRBN activity as a substrate receptor.
Purpose of the Study:
- To summarize recent advancements in CRBN-CRLA ubiquitin ligase research.
- To highlight the therapeutic applications of IMiDs in treating multiple myeloma.
Main Methods:
- Review of structural analyses of CRBN.
- Examination of the mechanism of IMiD binding to CRBN.
- Analysis of IMiD-induced degradation of transcription factors.
Main Results:
- CRBN's unique substrate receptor activity modulated by IMiDs.
- Specific and controlled degradation of transcription factors.
- Therapeutic efficacy of IMiDs in multiple myeloma models.
Conclusions:
- IMiDs, by targeting CRBN, offer a novel therapeutic strategy for multiple myeloma.
- Understanding CRBN-CRLA ubiquitin ligase function is crucial for drug development.
- Continued research into IMiDs and CRBN holds significant promise for cancer therapy.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.9K
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.6K
Related Concept Videos
01:10Drugs that Destabilize Microtubules
4.4K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
01:07Teratogenicity
4.6K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.6K
02:50Combination Therapies and Personalized Medicine
6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
72
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
01:15Drugs that Stabilize Microtubules
2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K